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 Aim: A recently discovered enzyme, indoleamine 2,3-dioxygenase (IDO), is expressed in placenta, dendritic cells and also in many 
kinds of tumors and in tumor-infiltrating macrophages. By catabolizing tryptophan, IDO causes local depletion of this essential 
amino acid and excess of kinurenin, and suppresses in situ proliferation and functioning of T lymphocytes. Thus, immune resistance 
of tumors can be overcome by inhibiting IDO activity. Materials and Methods: C3HA mice immunized with non-syngeneic H-29 tu-
mor were used to study the effect of the IDO inhibitor ethyl pyruvate, under systemic or local (at site of tumor cells localization) ad-
ministration, on the occurrence and rate of rejection of the second transplants of this tumor. Results: Both systemic and local admin-
istration of ethyl pyruvate increases the incidence of and substantially accelerates tumor regression as compared with control. Conclu-
sion: IDO inhibitors impairing immune resistance of tumors may appear useful in leveraging the efficacy of antitumor therapy.
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Since it was shown in 1998 that the capacity 
of an allogeneic embryo to escape rejection by the 
mother may somehow involve tryptophan catabo-
lism [1], a possible mechanism of maternal immune 
tole rance has been widely investigated. Quite soon 
it was found that indoleamine 2,3-dioxygenase (IDO), 
an enzyme expressed in trophoblast and catabolizing 
tryptophan via the kynurenine pathway, is respon-
sible for local depletion of the essential aminoacid 
tryptophan and accumulation of its toxic catabolites 
affecting T-cells [2, 3]. Suppression of IDO in the ex-
periments with pregnant mice resulted in the rejection 
of allogeneic but not syngeneic embryos [1]. In onco-
logy, these findings are critical for understanding how 
an intrinsically immunogenic tumor avoids or may 
avoid the immune attack in the host [4]. As a matter 
of fact, IDO was found to be expressed in various 
tumor cells and in tumor-infiltrating macrophages 
[5, 6]. In such cases high tumor IDO expression can 
predict unfavorable prognosis [4, 6, 7]. IDO inhibitors 
on their own slow down tumor progression and can 
enhance the therapeutic efficacy of a chemotherapy 
drug [8, 9]. A synthetic analog of tryptophan, D-
1-methyl-tryptophan, is widely used as IDO inhibitor 
[9]. It is administered into animals chronically at daily 
doses up to 800 mg/kg b.w. [9]. However, since the 
IDO-induced immune tolerance to tumors can be over-
come by suppressing the enzyme in the tumor cells 
and in tumor-infiltrating macrophages only, the dose 
of IDO inhibitor (and treatment costs) can be signifi-
cantly reduced if the inhibitor is administered locally 
at tumor site. On the other hand, one of the recently 
discovered IDO-inhibiting compounds, ethyl pyruvate, 
a comparatively inexpensive and low-toxic anti-inflam-
matory agent, has drawn our attention [10, 11]. In the 
present study with the use of mice with an intrinsically 
immunogenic non-syngeneic  tumor it was shown that 
chronic, systemic or local at tumor site, administration 
of ethyl pyruvate accelerates tumor rejection as com-
pared with control.
Mice of C3HA strain and the transplantable tu-
mor, Hepatocarcinoma-29 (H-29), were used [12]. 
All experimental procedures were perfomed in ac-
cordance with the normative rules of bioethics. The 
H-29 tumor originates from CBA mice but is trans-
plantable to 100% of C3HA mice. In a considerable 
part of the grafted mice the tumor eventually stops 
to progress and regresses. At the preparatory stage, 
5 x 105 H-29 cells were inoculated into the femur 
muscle of C3HA male mice. A month later the animals 
with progressing tumors were culled. A considerably 
higher dose of tumor cells (fivefold and tenfold) was 
then transplanted to immune animals which rejected 
the tumor. After that the animals were divided into two 
groups. The animals of one group were administered 
ethyl pyruvate for IDO inhibition, the other group was 
used as control. In the experiment with the systemic 
administration of ethyl pyruvate the inhibitor was dis-
solved in Ringer’s solution (5 mg/ml) and administered 
intraperitoneally twice a day for 20 days. Control mice 
received no injections. In the experiment with local 
administration, 0.1 ml of 1% ethyl pyruvate solution 
was administered intramuscularly at tumor site once 
a day during 10 days after tumor cells inoculation. 
Control animals in the same manner were administered 
by 0.1 ml of saline. At regular intervals tumors were 
palpated and measured with a vernier caliper. The 
time of tumor resorption was registered. The experi-
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ment was concluded 10 days after regression of the 
last tumor in the experimental group. The φ-criterion 
and Fischer’s arcsin transformation were used to test 
the validity of differences in tumor regression values 
(percentage of mice with regressed tumors) between 
the experimental and control groups.
In our previous study, under primary H-29 transplan-
tation to non-syngeneic C3HA mice the inhibition of IDO 
by D-1-methyl-tryptophan resulted in enhancement 
rather than suppression of tumor outgrowth [13]. The 
effect observed may appear paradoxical at first sight. 
Actually, an arising tumor and primary tumor transplants 
develop in the so-called pathologic immune privilege 
conditions [14] with a complex immune response that 
may suppress tumor growth or enhance it. In this case, 
IDO inhibition may cause not only the proliferation 
of T-killer and T-helper cells but may also activate sup-
pressor T-cells (Treg) contributing to the development 
of immune tolerance in the host, thereby enhancing the 
growth of the tumor. On the contrary, the clinicians have 
usually to deal with tumors which immune relationships 
with the host are explicit and which use IDO to suppress 
the effector phase of immune response. For this reason 
in the experiments on the tumor-suppressing potential 
of IDO inhibitors it is reasonable to use preimmunized 
animals. In the present study tumor recipients were 
tumor-grafted mice who rejected the tumors had been 
transplanted earlier.
At the preparatory stage for the first experiment, 
H-29 tumor cells were inoculated into the femur muscle 
of forty intact four-month old mice of C3HA strain 
at a dose of 5 x 105 cells. After a week tumors develo-
ped in all animals; subsequently tumor progression 
was observed in 13 animals and tumor inhibition and 
eventual regression – in 27 animals. The mice with tumor 
progression were culled. The mice rejecting the tumor 
transplant were re-inoculated with a significantly higher 
(fivefold, 1 x 106) dose of tumor cells at in the same 
femur muscle. Immediately after tumor cell inocula-
tion the mice were divided into 2 groups. In the control 
group 13 animals were kept without any exposure. 
In the experimental group, 14 animals were exposed 
to injections of ethyl pyruvate twice a day as described 
in METHODS. The ethyl pyruvate injections at a single 
dose of 40 mg/kg were performed 40 times with a total 
course dose of about 1.6 g/kg b.w. As shown in Fig. 1, 
ten days after the transplantation tumors developed 
in 100% of the mice of both groups and then began 
to regress. During the first 4 days the rate of tumor re-
gression was the same for both groups, and then some-
what faster in the experimental group as compared 
with control. Twenty six days after the transplantation 
the tumors regressed in all animals except two of the 
control group. Subsequently the tumor regressed in one 
animal and recurred and killed the other.
A month after tumor rejection the survived mice 
were used for H-29 cells inoculation at a dose higher 
than that used in the previous transplantation (5 x 106). 
After the transplantation the treated and untreated 
mice were divided equally between the experimental 
and control groups of the new experiment. The groups 
were enlarged by 4–5 mice with regressed tumors, 
which became available by that time, and then ex-
posed to treatment (daily local administration of ethyl 
pyruvate or saline, see MATHERIAL AND METHODS).
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Fig. 1. Dynamics of H-29 transplant regression in C3HA mice 
under systemic administration of ethyl pyruvate, an inhibi-
tor of indoleamine 2,3-dioxygenase (light circles), and in the 
control (dark circles). 40 doses of 40 mg/kg of the agent were 
administered intraperitoneally twice a day during 20 days after 
tumor cells inoculation. There are 13–14 animals in each group
Six days after tumor cells inoculation, tumors ap-
peared in all animals of both groups. The average tumor 
volume was 0.30 ± 0.031 cm3 for control and 0.20 ± 
0.045 cm3 for the experimental group. Two days later the 
average tumor volume was 0.23 ± 0.031 cm3 and 0.14 ± 
0.034 cm3,  respectively (insignificant differences). The 
tumors eventually diminished in both groups, but they 
became nonpalpable (fully regressed) at an earlier 
time and in more individuals treated with ethyl pyru-
vate as compared with control animals (Fig. 2). In both 
experiments ethyl pyruvate produced no notable toxic 
effect: both under systemic and local administration the 
mice’s body weight decreased by less than 4% upon 
completion of the course.
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Fig. 2. Dynamics of H-29 transplant regression in C3HA mice 
under local administration of ethyl pyruvate, an inhibitor of indole-
amine 2,3-dioxygenase (light circles), or saline (dark circles). 
0.1 ml of 1% ethyl pyruvate solution (or saline in control) was 
administered intramuscularly at tumor site once a day during 
10 days after tumor cells inoculation. There were 17 animals 
in each group. Asterisk marks a significant difference from the 
control (p < 001)
Thus, the results indicate that chronic, systemic 
or local, administration of ethyl pyruvate at a non-toxic 
dose to preimmunized mice results in an accelerated 
rejection of the repeated tumor transplants. In the 
present study (in particular in the first experiment) 
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we used a cumbersome regimen of ethyl pyruvate 
administration recommended by the authors who first 
suggested it as IDO inhibitor [11]. At the same time, 
from the literature ethyl pyruvate is known to be a food 
additive [10, 11], implicating it should retain at least 
some of its activity under per os administration. There-
fore, it can not be excluded that ethyl pyruvate may 
inhibit IDO not only under parenteral administration. 
This question requires further investigation. Thus, 
future research is to focus on the applicability and 
clinical prospects of ethyl pyruvate (and/or other IDO 
inhibitors) for the treatment of tumors in combination 
with common chemotherapy drugs.
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